Daniela Marino, PhD, Co-founder and CEO of CUTISS, has shared her insights into the development of denovoSkin™, an innovative bio-engineered skin graft designed to improve skin reconstruction outcomes. Currently in the late stages of clinical trials, denovoSkin™ is an autologous dermo-epidermal skin graft that aims to offer significant advantages over traditional autografting, which is the current standard in skin surgery.
Marino, who transitioned from academia to biotech to pursue her passion for regenerative medicine, emphasized the importance of blending both “deep science” and “deep tech” to push the boundaries of skin tissue therapeutics. She believes that the integration of advanced technology and scientific research is crucial for the future of skin engineering, especially in the areas of tissue engineering and skin pigmentation.
Early clinical data from trials suggest that denovoSkin™ can potentially reduce the common issues associated with autografting, particularly the morbidity caused by donor site injuries. The product is also showing promise in improving both the aesthetic and functional outcomes for patients, a critical factor for those in need of skin reconstruction after severe burns or injuries.
Looking to the future, Marino discussed CUTISS’s focus on automation, which could revolutionize skin surgery and dermatology by enabling more personalized tissue therapies. This automation is expected to play a key role in the commercial rollout of denovoSkin™, as the company prepares for market access.
Through her personal experiences, Marino identified new opportunities within regenerative medicine and tissue engineering. Her journey highlights the potential of bio-engineered skin grafts to change the way skin surgeries are performed, offering hope for improved patient outcomes.
Marino also shared her thoughts on the future of skin engineering, noting that lessons learned along her journey will play a pivotal role in shaping the next generation of autologous, bio-engineered skin grafting solutions. The development of denovoSkin™ is part of a broader movement in regenerative medicine that could eventually change the landscape of skin surgery.
Related Topics:
